Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 517 participants.

Also called NCT02585778

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 517 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02585778
  • EudraCT 2015-000799-92
Other papers using this trial's data
  • Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM-INSULIN randomized trial Diabetes, obesity & metabolism, 2017-12 DOI, PubMed 28905478, PMC5698740 In the PMC Open Access subset under CC BY-NC-ND.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Austria, Belgium, France, Germany, Italy, Netherlands, Spain, Switzerland, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02585778. Randomized; double masking; primary purpose treatment. Start 2015-10-23 (actual); primary completion 2017-04-03 (actual). Results posted on 2018-05-17.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)
Condition
Hypercholesterolaemia
Intervention (Drug)
Alirocumab
Intervention (Drug)
Placebo
Intervention (Drug)
Lipid-Modifying Therapy (LMT)
Intervention (Drug)
Antihyperglycemic Drug
Lead sponsor
Sanofi (class: industry)
Collaborator
Regeneron Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct02585778
Content hash
50dab2e9f8a96a44d8cfd90acf0d8646de773ee91544e432b7845236cd2fd627